Patients on either medication typically follow the same escalation timeline: weeks 1-4 at 0.25 mg, weeks 5-8 at 0.5 mg, weeks 9-12 at 1.0 mg, weeks 13-16 at 1.7 mg, and weeks 17+ at the 2.4 mg maintenance dose
Mandel KG, Daggy BP, et al
(6) Animal and human studies link higher 16-alpha-hydroxyestrone levels with greater breast cell growth and cancer risk development
As we stand on the cusp of breakthroughs in obesity treatment, GLP-1 agonists appear poised to play a significant role in shaping the future landscape of weight management strategies
Important Safety Info for GLP-1s See Important Safety Information, including Boxed Warning, about: Important Safety Information for Wegovy (semaglutide) injection Warning: Risk of Thyroid C-Cell Tumors In studies with mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused thyroid tumors, including thyroid cancer
Peptides are not a fad